Tristram Ryan is currently undertaking his PhD in the School of Biochemistry and Immunology in Trinity College Dublin, Ireland, in the laboratory of Professor Luke O'Neill. He is studying the role of immunomodulatory drugs in the treatment of inflammation-driven coagulation, termed immunothrombosis, which occurs in conditions such as sepsis and disseminated intravascular coagulation. Tristram is a science enthusiast involved in public engagement and the dissemination of scientific results. He has presented his work at international conferences and as Chairperson of the Trinity College Biochemical Society, organized and hosted a multidisciplinary series of seminars involving scientific leaders from around the world.

Professor Luke O'Neill FRS is the Chair of Biochemistry and Immunology (1960) at Trinity College Dublin, Ireland. He completed his PhD in Pharmacology at the University of London, UK. The O'Neill laboratory has made significant discoveries in our understanding of immune cell signaling pathways, and works on the molecular basis to the inflammatory response, in particular the role of macrophages in regulating human health and disease Professor O'Neill's work has led to the development of novel anti-inflammatory therapies, and he has co-founded the companies Inflazome, which developed anti-NLRP3 inhibitors and was acquired by Roche Ltd in 2020, and Sitryx. Professor O'Neill has received several prestigious international awards, being elected a member of the Royal Irish Academy in 2004, the European Molecular Biology Organisation in 2005, and a Fellow of the Royal Society (FRS) in 2016. He published 4 best-selling scientific books and appearing weekly on Irish radio.